CCM
UTHR icon

Camber Capital Management’s United Therapeutics UTHR Stock Holding History

Camber Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-400,000
Closed -$31.9M – 36
2019
Q3 		$31.9M Buy
400,000
+32,471
+9% +$2.61M 1.68% 24
2019
Q2 		$28.7M Buy
+367,529
New +$34.4M 1.34% 24

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Camber Capital Management's UTHR Position: Q4 2019 in Review

Camber Capital Management sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 400,000 shares — an estimated $31.9M sold.

Camber Capital Management first reported a position in UTHR in Q2 2019 and held it in 2 quarters. The position peaked at $31.9M in Q3 2019. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

  • Camber Capital Management reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Camber Capital Management sold 400,000 United Therapeutics shares in Q4 2019, an estimated $31.9M.
  • Camber Capital Management first reported a position in United Therapeutics in Q2 2019 and held it in 2 quarters.
  • Camber Capital Management's United Therapeutics position peaked at $31.9M in Q3 2019.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Camber Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.